Sequentscientific earnings calls.
Other · 2 quarters tracked · source-linked performance, management guidance and promise context.
Latest revenue
₹424 Cr
financial record pending verification
Quarters tracked
2
source records in the directory
Delivery assessment
100
Across 4 tracked commitments: 4 delivered, 0 missed.
Call date
2025-11-19
latest available source date
Signal trajectory
2 actual quartersCurrent read
100/100
Across 4 tracked commitments: 4 delivered, 0 missed.
Latest source read
What changed this quarter?
SeQuent Scientific delivered a strong Q2 FY26 with 15% YoY revenue growth to Rs 424 crore, driven by robust 18% growth in formulations (75% of sales) and 7% growth in API. EBITDA surged 47% YoY to Rs 65.7 crore with margin expansion of 330 bps to 15.5%, marking the company's crossing of its 15% EBITDA margin target. PAT nearly tripled to Rs 19.6 crore. Vash Life Sciences (consolidated entity post-merger) reported Q2 revenue of Rs 428 crore with 96% EBITDA growth and margin expansion to 28%. The NCLT approved the SeQuent-Vash merger on November 18, 2025, enabling combined reporting from Q3. Management targets 20%+ EBITDA margins going forward, sustained by CDMO contracts, new product launches (8 US launches in FY26), and manufacturing synergies. India formulations (6% growth this quarter) should accelerate in H2 from field force expansion. Key risks include SeQuent API tracking below Rs 100 crore run rate until Q4, though management remains confident of reaching that threshold in FY27.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Positive
Revenue
₹424 Cr
Source date
2025-11-19
Across the record
Quarter history.
History modules